drugset / Trial / NCT02963350
A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease
Summary
* To provide access to BMN 190 to patients with CLN2 disease who cannot participate in a clinical trial. * To collect additional information on the safety and tolerability of BMN 190 administration in patients with CLN2 disease.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cerliponase Alfa | Protein / enzyme biologic | — | — |